Resverlogix Closes $10M of Equity Subscriptions

CALGARY, June 20, 2017 /CNW/ – Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) today closed its previously-announced offering, issuing a total of $10 million of its equity units.

Eastern Capital Limited (“Eastern”) and Shenzhen Hepalink Pharmaceutical Co., Ltd. (“Hepalink”) purchased a total of 2,951,313 equity units at a price of $1.80 per unit for aggregate proceeds of $5.3 million pursuant to a non-brokered private placement. Eastern and Hepalink purchased 1,617,980 and 1,333,333 equity units, respectively. In addition, under the previously-announced overnight marketed equity offering conducted by Bloom Burton Securities Inc., subscribers purchased an additional 2,552,489 equity units at a price of $1.80per unit for aggregate proceeds of an additional $4.6 million.

Read the full press release here.